

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
13 March 2008 (13.03.2008)

PCT

(10) International Publication Number  
**WO 2008/028956 A1**

(51) International Patent Classification:  
**A61K 39/13** (2006.01)

(74) Agents: **LUBIENSKI, Michael John** et al.; Glaxo-SmithKline, Corporate Intellectual Property CN925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(21) International Application Number:  
PCT/EP2007/059390

(22) International Filing Date:  
7 September 2007 (07.09.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0617602.8 7 September 2006 (07.09.2006) GB  
0625593.9 21 December 2006 (21.12.2006) GB

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): **GLAXO-SMITHKLINE BIOLOGICALS S.A.** [BE/BE]; rue de l'Institut 89, B-1330 Rixensart (BE).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DE HEMPTINNE, Herve** [BE/BE]; GlaxoSmithKline Biologicals s.a., rue de l'Institut 89, B-1330 Rixensart (BE). **DUCHENE, Michel** [BE/BE]; GlaxoSmithKline Biologicals s.a., rue de l'Institut 89, B-1330 Rixensart (BE). **MARY, Anne** [BE/BE]; GlaxoSmithKline Biologicals s.a., rue de l'Institut 89, B-1330 Rixensart (BE). **SONVEAUX, Marc** [BE/BE]; GlaxoSmithKline Biologicals s.a., rue de l'Institut 89, B-1330 Rixensart (BE).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(54) Title: VACCINE

(57) Abstract: The standard dose of polio vaccines contains 40 D-antigen units of inactivated poliovirus type 1 (Mahoney), 8 D-antigen units of inactivated poliovirus type 2 (MEF-1), and 32 D-antigens units of inactivated poliovirus type 3 (Saukett). The present invention teaches that reduced doses of inactivated poliovirus can maintain an adequate or improved level of protection against polio.

WO 2008/028956 A1